Diabetes Archives

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 28 Jul 2020

Record Series A for Italian Biotech Funds Autoimmune Therapy

Italian biotech Enthera raised €28M in Series A funding to develop its drug candidate for type 1 diabetes and inflammatory bowel disease and take it to human trials. Enthera was founded in 2016 and is the first company to ‘graduate’ from the BiovelocITA accelerator program in Milan, which is supported by French life science investor […]

July 28, 2020 - 3 minutesmins - By Helen Albert

In Depth 3 Mar 2020

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

sigrid therapeutics type 2 diabetes sweden

Startup Scout 7 Feb 2020

Sigrid Therapeutics Prevents Type 2 Diabetes Using Silica Powder in the Gut

In Stockholm, Sweden, Sigrid Therapeutics is developing an ingestible silica powder that can treat type 2 diabetes and obesity without being absorbed in the gut. Mission: To produce the first prophylactic silica-based treatment for type 2 diabetes that does not enter the bloodstream. Some people have higher blood sugar levels than normal, but not high […]

February 7, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Feb 2020

Valbiotis Teams up with Nestlé to Reduce Type 2 Diabetes Risk

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M […]

February 6, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Nov 2019

Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes

A genetic mutation common to Finnish populations has been found to protect against type 2 diabetes by increasing insulin in the blood, providing a potential target for new drugs. The mutation is found in at least 0.2% of the population in western Finland, whereas it only appears in 0.02% of other European populations. The mutation […]

November 4, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 30 Sep 2019

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […]

September 30, 2019 - 4 minutesmins - By Editorial Team

novo nordisk type 2 diabetes semaglutide

News and Trends 23 Sep 2019

FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug

The first oral drug for type 2 diabetes belonging to the class of GLP-1 agonists, developed by Novo Nordisk, has got the go-ahead from the FDA. The Danish company is known for its blockbuster injectable drug in the same class — liraglutide — that is now one of the most highly prescribed drugs in the […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

DIY diabetes community artificial pancreas

In Depth 2 Sep 2019

How the DIY Diabetes Community Made the Artificial Pancreas Possible

Six years ago, his three-year-old daughter was diagnosed with type 1 diabetes. This led Milos Kozak, a software developer from Prague, to join the DIY diabetes community. “After the diagnosis, I started to look for some solutions because I was really disappointed by the technology available on the market for diabetes,” Kozak told me. That’s […]

September 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

imcyse type 1 diabetes insulin immunotherapy

News and Trends 28 Aug 2019

Type 1 Diabetes Immunotherapy Shows Promise in Phase I

An immunotherapy designed by the Belgian biotech Imcyse to prevent type 1 diabetes has shown signs of clinical benefits and no major safety issues in a phase I trial. The phase I trial recruited 41 patients newly diagnosed with type 1 diabetes. Imcyse injected the patients with different doses of its treatment and monitored the […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Jul 2019

French Biotech’s Plant Extract Cuts Blood Glucose in Prediabetic People

A plant extract developed by the French biotech Valbiotis is the first food supplement to reduce blood glucose levels in people at high risk of developing type 2 diabetes. In a phase IIa trial, Valbiotis compared its food supplement with a placebo in 51 people with prediabetes. After six months, the supplement had reduced blood […]

July 5, 2019 - 2 minutesmins - By Jonathan Smith

acne s biomedic skinbiotherapeutics skin microbiome

News and Trends 2 Jul 2019

Microbiome Food Supplement Improves Metabolic Syndrome in Overweight People

A food supplement made from bacteria, developed by a Belgian research group, has improved symptoms of the metabolic syndrome including insulin resistance and high blood cholesterol levels in overweight volunteers at risk of heart disease and type 2 diabetes. The metabolic syndrome is a collection of conditions including high blood cholesterol, insulin resistance and high […]

July 2, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us